Sign In
Buy RNXT
RenovoRx Earnings Calls
| Release date | Aug 13, 2026 |
| EPS estimate | -$0.0800 |
| EPS actual | - |
| Revenue estimate | 703.75K |
| Revenue actual | - |
| Expected change | +/- 8.21% |
| Release date | May 14, 2026 |
| EPS estimate | -$0.0800 |
| EPS actual | -$0.0800 |
| Revenue estimate | 469.5K |
| Revenue actual | 563K |
| Revenue Surprise | 19.91% |
| Release date | Mar 30, 2026 |
| EPS estimate | -$0.0800 |
| EPS actual | -$0.0800 |
| Revenue estimate | 419.7K |
| Revenue actual | 238K |
| Revenue Surprise | -43.29% |
| Release date | Nov 13, 2025 |
| EPS estimate | -$0.0800 |
| EPS actual | -$0.0800 |
| Revenue estimate | 405.4K |
| Revenue actual | 266K |
| Revenue Surprise | -34.39% |
Last 4 Quarters for RenovoRx
Below you can see how RNXT performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Nov 13, 2025 |
| Price on release | $0.97 |
| EPS estimate | -$0.0800 |
| EPS actual | -$0.0800 |
| Date | Price |
|---|---|
| Nov 07, 2025 | $0.96 |
| Nov 10, 2025 | $1.00 |
| Nov 11, 2025 | $1.07 |
| Nov 12, 2025 | $1.00 |
| Nov 13, 2025 | $0.97 |
| Nov 14, 2025 | $0.750 |
| Nov 17, 2025 | $0.80 |
| Nov 18, 2025 | $0.782 |
| Nov 19, 2025 | $0.733 |
| 4 days before | 1.34% |
| 4 days after | -24.83% |
| On release day | -23.03% |
| Change in period | -23.82% |
| Release date | Mar 30, 2026 |
| Price on release | $1.07 |
| EPS estimate | -$0.0800 |
| EPS actual | -$0.0800 |
| Date | Price |
|---|---|
| Mar 24, 2026 | $1.08 |
| Mar 25, 2026 | $1.10 |
| Mar 26, 2026 | $1.16 |
| Mar 27, 2026 | $1.13 |
| Mar 30, 2026 | $1.07 |
| Mar 31, 2026 | $1.01 |
| Apr 01, 2026 | $0.97 |
| Apr 02, 2026 | $0.98 |
| Apr 06, 2026 | $0.93 |
| 4 days before | -0.93% |
| 4 days after | -12.91% |
| On release day | -5.61% |
| Change in period | -13.71% |
| Release date | May 14, 2026 |
| Price on release | $0.86 |
| EPS estimate | -$0.0800 |
| EPS actual | -$0.0800 |
| Date | Price |
|---|---|
| May 08, 2026 | $0.86 |
| May 11, 2026 | $0.85 |
| May 12, 2026 | $0.87 |
| May 13, 2026 | $0.85 |
| May 14, 2026 | $0.86 |
| May 15, 2026 | $0.82 |
| May 18, 2026 | $0.783 |
| May 19, 2026 | $0.81 |
| May 20, 2026 | $0.81 |
| 4 days before | -1.00% |
| 4 days after | -5.25% |
| On release day | -4.09% |
| Change in period | -6.19% |
| Release date | Aug 13, 2026 |
| Price on release | - |
| EPS estimate | -$0.0800 |
| EPS actual | - |
| Date | Price |
|---|---|
| Jul 27, 2026 | $0.97 |
| Jul 28, 2026 | $0.91 |
| Jul 29, 2026 | $0.90 |
| Jul 30, 2026 | $0.94 |
| Jul 31, 2026 | $0.96 |
RenovoRx Earnings Call Transcript Summary of Q1 2026
RenovoRx reported its strongest quarter to date with Q1 2026 revenue of $563k, a 136% sequential increase and representing ~51% of 2025 revenue. Management attributes the growth to deliberate commercial execution and rapid expansion of active commercial cancer centers (from 8 at year-end 2025 to 16 as of May 2026) with a pipeline of 32 additional centers. The company reiterated full-year 2026 revenue guidance of $3.0–$4.0 million and expects Q2 revenue to exceed Q1. Gross margin was high (85.1%) in Q1; R&D was $1.2M and SG&A was $2.7M. RenovoRx closed an oversubscribed private placement in March raising ~$10M (total cash ~$12.4M as of March 31, 2026), which management says provides runway into H2 2027. The Phase 3 TIGeR-PaC trial is near enrollment completion (106 of 114 randomized as of May 14, 2026) with final data expected mid–late 2027; conversion of trial sites to commercial centers is expected to drive further revenue in H2 2026. Management emphasized physician-driven repeat orders, favorable toxicity profile versus systemic chemo, modest near-term R&D needs for device optimization, and a capital-efficient strategy including investigator-initiated and registry studies to broaden use cases.
